You are here

2seventy bio

2seventy Bio stops enrolling patients in blood cancer therapy study

Reuters

Wed, 09/25/24 - 11:56 am

Bristol Myers Squibb

Multiple Myeloma

clinical trials

FDA Adcomm to Tackle Complexity of CAR-T for Multiple Myeloma

BioSpace

Mon, 03/11/24 - 11:53 am

Multiple Myeloma

Bristol Myers Squibb

2seventy bio to sell experimental cell therapies, names new CEO

Reuters

Tue, 01/30/24 - 10:23 am

FDA to delay decision on Bristol Myers-2seventy bio cancer therapy

Reuters

Mon, 11/20/23 - 10:12 am

Bristol Myers Squibb

2Seventy CEO Leschly to step down as company cuts staff, spending

BioPharma Dive

Tue, 09/12/23 - 11:53 am

FDA puts 2seventy CAR-T trial on hold in wake of patient death

Fierce Biotech

Mon, 08/14/23 - 10:06 am

clinical trials

Death triggers pause of 2seventy CAR-T cell therapy leukemia trial

Fierce Biotech

Wed, 06/14/23 - 10:18 am

clinical trials

Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma

BioPharma Dive

Wed, 08/10/22 - 11:34 pm

Bristol Myers Squibb

Multiple Myeloma

2seventy bio's honeymoon phase is over as job cuts hit 6% of staff

Fierce Biotech

Wed, 03/23/22 - 11:10 am

As Abecma sales take off, Bristol Myers and 2seventy scrap a follow-up CAR-T

Endpoints

Thu, 01/13/22 - 07:21 am

Bristol Myers Squibb

Bluebird bio completes spinout of oncology business 2seventy bio

Bizjournals

Fri, 11/5/21 - 12:00 am

bluebird bio provides update on 2seventy bio spin-off

PM Live

Tue, 10/12/21 - 11:49 pm

Bluebird names oncology spinoff, establishes leadership team

Fierce Biotech

Thu, 05/6/21 - 10:58 am